Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antithrombotic recombinant antibodies].

Julien Muzard1, Stéphane Loyau, Nadine Ajzenberg

  • 1Inserm, U698, Hôpital Bichat, 46, rue Henri Huchard, Paris, France.

Journal De La Societe De Biologie
|July 27, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Calibration of Flow Cytometers Enables Reproducible Measurements of Extracellular Vesicle Concentrations and Reference Range Establishment.

Journal of extracellular vesicles·2025
Same author

Platelet protease nexin-1 limits fibrinolysis in patients with cirrhosis.

JHEP reports : innovation in hepatology·2025
Same author

Neutrophil extracellular traps-targeting therapy with deoxyribonuclease 1 reduces large vessel occlusion-induced downstream microvascular thromboinflammation in a rat model of stroke.

Research and practice in thrombosis and haemostasis·2025
Same author

Prevention of hemorrhage after implantation of mechanical circulatory support with a purified von Willebrand factor concentrate: results of the early terminated randomized controlled trial.

Journal of thrombosis and haemostasis : JTH·2025
Same author

SerpinE2 deficiency exacerbates glomerular injury in diabetic nephropathy through dysregulated angiogenesis and inflammatory responses.

American journal of physiology. Renal physiology·2025
Same author

Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs.

European heart journal·2025
Same journal

[Food safety of GMOs].

Journal de la Societe de biologie·2010
Same journal

[Placing on the market, breeders rights and growing genetically modified (GM) varieties].

Journal de la Societe de biologie·2010
Same journal

[Cultivation and environmental impacts of GMO crops].

Journal de la Societe de biologie·2010
Same journal

[Applications of genetically modified animals].

Journal de la Societe de biologie·2010
Same journal

[Why GMOs].

Journal de la Societe de biologie·2010
Same journal

[Mutations in renin-angiotensin system genes and kidney developmental anomalies].

Journal de la Societe de biologie·2010
See all related articles

Ischaemic arterial diseases cause millions of deaths globally. New antithrombotic therapies targeting platelet activation are needed to improve outcomes beyond current treatments like abciximab.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Context:

  • Ischaemic arterial diseases, including coronary syndromes and stroke, are leading global causes of mortality.
  • Cardiovascular diseases claim 17 million lives annually, with projections indicating an increase to 24 million by 2030.
  • Despite current therapies like thrombolysis, antiplatelet drugs, and angioplasty, 6-month morbidity and mortality rates following acute coronary syndromes remain high at 8-15%.

Purpose:

  • To address the clinical need for improved treatments for ischaemic cardiovascular diseases.
  • To explore novel therapeutic targets beyond the final stage of platelet aggregation.
  • To review potential targets for developing new antithrombotic antibodies.

Summary:

  • Acute ischaemic syndromes stem from platelet-rich clots forming at sites of coronary stenosis and atherosclerotic plaque erosion.

Related Experiment Videos

  • Current treatments, including the antibody abciximab (c7E3), target the final phase of platelet aggregation but are associated with complications like hemorrhage and thrombocytopenia.
  • The review focuses on platelet receptors involved in earlier activation steps, identifying them as potential targets for novel antithrombotic antibody development.

    • Impact:

    • Highlights the limitations of existing antithrombotic therapies and the significant unmet clinical need.
    • Identifies earlier platelet activation pathways as promising targets for next-generation antithrombotic drug development.
    • Provides a foundation for the discovery of new molecules to combat ischaemic cardiovascular diseases more effectively.